Markers for individualised therapy in endometrial carcinoma.
about
Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancerWhat Is the Best Preoperative Imaging for Endometrial Cancer?New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical careHypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.Switch in FOXA1 status associates with endometrial cancer progressionThe IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting ApproachesClinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer.Creation of the Polish version and adaptation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (QLQ-EN24)Estimated intermediate risk endometrial cancer: debate and new perspectives on therapy individualization and prognosis establishment starting from a peculiar case.High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors.A pan-cancer proteomic perspective on The Cancer Genome Atlas.The emerging genomic landscape of endometrial cancer.Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancerHigh-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutatedIntegrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.Upregulation of TrkB promotes epithelial-mesenchymal transition and anoikis resistance in endometrial carcinoma.Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas.Implications of a two-step procedure in surgical management of patients with early-stage endometrioid endometrial cancer.DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer.Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors.Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma.Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer.Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parametersESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinomaATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma.Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancerRecurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growthA Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 BindingIndividualised proteome profiling of human endometrial tumours improves detection of new prognostic markers.The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.An update of the classical Bokhman's dualistic model of endometrial cancer.Understanding Molecular Landscape of Endometrial Cancer through Next Generation Sequencing: What We Have Learned so Far?Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas.FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype.Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
P2860
Q27852937-D8F58148-ECC7-46DD-99D8-5306010CFC72Q28077761-2DA9E652-74A5-4EE9-B5D5-86CF0CCD5015Q28078792-6B88C876-8055-444B-9D6B-6CF60395E0CCQ33572253-5FA9DDC6-A14F-430A-85A6-46805D4184D2Q33645463-B746923D-F1F5-440F-A2CA-B039D6A0906AQ33658023-0356BC96-5A01-4A55-B51D-B53D24594158Q33671093-4AF8D6B2-3795-4040-ADC9-47CE345E353BQ33799256-27A23D80-32C9-4ED1-B417-8535CB335AE1Q33802919-5009DB19-096D-4C39-AA63-162812BBF8B1Q33877440-495A21C2-DB1B-446F-9710-8E702C91BDAFQ33944976-51EA84CC-1A35-4D7E-A588-1C018B0E087EQ34026976-D1A163D9-A67A-48C9-B68E-E4153EB83641Q34310001-949BDFBC-649A-473C-B956-9852586B721AQ34541232-48198789-9E61-4A48-89E0-CE82C08B3C02Q34580883-0085F6BC-FF70-4E63-B8FF-6426DAACF740Q34923263-28C9BE30-615E-48DE-B8E0-0DF11EDC25D0Q35121869-F8202810-97CF-4B5E-AEDE-7F0D09CCB295Q35419055-4C5FEF03-6B81-444D-BB03-BEBFE1BC7F48Q35603652-255B7580-1E68-4C14-BEB3-DC2A96CCE306Q35739831-06B4258D-6BB6-4F5E-BAAC-F1A4664A1948Q35740059-2E3E7D68-99D3-4DAA-A9B7-7CF670D1BB83Q35833089-0A33F97E-260A-4C5D-A854-B92E53397246Q35879733-DBE5E7BC-A5D4-4D85-83C1-CC1380447212Q36027067-5BBB8643-8A74-4AE2-BCDF-AB842C44E91DQ36372293-183B74BC-6CC9-4AF2-A491-61D4344EC17BQ36413463-EB43681B-88FD-44B0-9F0C-0C347B7A6EDEQ36414073-5DE4B10F-7968-4EFB-8763-53770E265FEFQ36418630-5CA5F40B-821F-42EE-BB7D-EB336DABEE6EQ36471479-7452E6A2-D283-42E1-AC21-2E86024864DBQ36750990-CEBD438F-2A70-45C5-8418-F15832E12F16Q36801208-ECBB3E42-3D2D-4D9D-85DC-8A26D497E941Q36886180-0E1885A7-6C28-4F76-8B76-A0061E3E623EQ37005064-F88AB4B1-A119-46C4-A5A7-BD17EC2756F4Q37081947-0B1CC01D-85A5-4ED4-8B9B-7B5A0ADCE2C7Q37131530-05563882-1EA0-4005-BF35-15D12AD56267Q37195410-D434F362-C533-4236-9E69-4CA0025507FEQ37382351-667E00F1-D593-47B7-B0B4-4114DA8008DFQ37459631-3F4AB920-0309-4ACD-87FE-91DD8DB2554FQ37486143-18C1E203-B96B-4148-B077-BAF0DE505734Q37524037-D0240913-7C19-408E-BE16-1D8014BF97E7
P2860
Markers for individualised therapy in endometrial carcinoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Markers for individualised therapy in endometrial carcinoma.
@en
type
label
Markers for individualised therapy in endometrial carcinoma.
@en
prefLabel
Markers for individualised therapy in endometrial carcinoma.
@en
P3181
P1433
P1476
Markers for individualised therapy in endometrial carcinoma.
@en
P2093
Helga B Salvesen
P304
P356
10.1016/S1470-2045(12)70213-9
P577
2012-08-01T00:00:00Z